AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03652129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disinfection
Description: Disinfection maneuver using LASER and nano irrigant
Study NCT03724305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy for Insomnia
Description: Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
Study NCT02613247 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hylan G-F 20
Description: Intra-articular injection of 6 mL Hylan G-F 20
Study NCT02708524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon C Contact Lens
Study NCT02708524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A Contact Lens
Study NCT02708524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B Contact Lens
Study NCT02708524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samfilcon A Contact Lens
Study NCT01876901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)
Description: 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation
Study NCT01876901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colo-anal anastomosis (CAA)
Description: After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch
Study NCT03082079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
Study NCT01719263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterVapor® treatment plus Optimal Medical Therapy
Description: Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
Study NCT01719263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
Study NCT01846442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
Study NCT01846442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA (0.25%)
Description: Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
Study NCT01846442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA (0.5%)
Description: Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
Study NCT01846442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA (1.0%)
Description: Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
Study NCT00061269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videoscopic-Assisted Retroperitoneal Debridement (VARD)
Study NCT02681991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renamezin capsule
Study NCT01405638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
Study NCT01870128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Steroid
Description: Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
Study NCT01870128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 15 to 25 mg PO per week
Study NCT01870128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination
Description: Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
Study NCT02930850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 Pulse oximeter
Description: Noninvasive pulse oximeter that measures hemoglobin
Study NCT02365636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 is an ointment applied topically twice daily to area of pain.
Study NCT00267774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve
Study NCT00267774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided PCI
Study NCT02365636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
Study NCT00355238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivanib (active)
Description: Tablet, Oral, Brivanib 800 mg, once daily, until progression
Study NCT03706235 — intervention group
Intervention type: OTHER
Intervention: Blood draw (venipuncture)
Description: Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
Study NCT02577315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
Study NCT02577315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
Study NCT02577315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
Study NCT02577315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
Study NCT02512107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Juice Plus+
Description: Dried fruit and vegetable juice capsule.
Study NCT00526058 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Secura then Futura
Description: Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
Study NCT00526058 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Futura then Secura
Description: Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
Study NCT02512107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT05866289 — intervention group
Intervention type: OTHER
Intervention: Prone position
Description: Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
Study NCT03363009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized group
Description: The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.
Study NCT03363009 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control group
Description: Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
Study NCT03063983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Continuous oral cyclophosphamide
Study NCT03063983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Continuous oral methotrexate
Study NCT02226029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~* Lipid emulsion 1: acid stable, particle size 0.6 µm~* Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~* 13C-markers will be mixed with emulsions
Study NCT04572425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided imagery
Description: 10 minutes of guided imagery experience delivered on tablet
Study NCT04572425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
Study NCT01746784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N6022
Description: Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
Study NCT01746784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
Study NCT02131792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slanted recession of the lateral rectus muscle
Description: All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
Study NCT01072734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Influenza vaccine
Study NCT03932695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose milk peptide
Description: what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
Study NCT03932695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose milk peptide
Description: what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
Study NCT02293278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
Study NCT01549171 — intervention group
Intervention type: DRUG
Intervention: Iloprost
Description: supplement in culture medium during culture in the lab. The concentration is 1 uM.
Study NCT01549171 — intervention group
Intervention type: OTHER
Intervention: normal saline
Description: Supplement with vehicle only no Iloprost.
Study NCT03527758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flo TracIQ with HPI software
Description: Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
Study NCT03932695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
Study NCT01233375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO-1.01
Description: 1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles.
Study NCT02199171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given via HIPEC
Study NCT02862158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDT visual field
Study NCT02862158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard HVF
Study NCT04186819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPSMA-7.3 (18F) Injection
Description: Radioligand for PET CT scanning
Study NCT02848976 — intervention group
Intervention type: OTHER
Intervention: Re-training to effort (RE)
Description: The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
Study NCT00614016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ST20
Description: single administration of oral dosage form
Study NCT03406507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
Study NCT01282918 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implantation w/o DF test
Description: ICD implantation without Defibrillation Test
Study NCT01988870 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative Radiation Therapy (IORT)
Description: IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
Study NCT00458133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
Study NCT01282918 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implantation with DF test
Description: ICD implantation with DF test according to standardized procedure
Study NCT03576625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Oleic Sunflower Oil
Description: Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
Study NCT03576625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buglossoides Oil
Description: Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
Study NCT01540019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paullinia cupana
Description: 50mg of Paullinia cupana as capsule, twice daily
Study NCT03852771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cirvo(TM) therapy
Description: The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.
Study NCT03537534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Jet Injector
Description: Applying Lidocaine following endourologic procedure
Study NCT03537534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Applying surgilube following endourologic procedure
Study NCT02574234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of apelin and inflammatory cytokines
Description: A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
Study NCT02574234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of cognitive functions
Description: Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
Study NCT02574234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid sampling cerebrospinal
Description: Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
Study NCT00458133 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
Study NCT02574234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative delirium research
Description: Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
Study NCT02574234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Residual cognitive dysfunction research
Description: Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
Study NCT01463631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3007113
Description: Administered orally
Study NCT03310281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOLD: Videogame
Description: Videogame-like digital therapy
Study NCT02847078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart phone app
Description: App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
Study NCT02847078 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: A guideline booklet
Description: A guideline booklet with general advice on secondary prevention of coronary artery disease.
Study NCT00823875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol group
Description: Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
Study NCT00823875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol group
Description: Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
Study NCT00823875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol + Probucol group
Description: Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
Study NCT00823875 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: control group
Description: routine treatment
Study NCT03604198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relacorilant
Description: CORT125134 is supplied as capsules for oral dosing.
Study NCT02603341 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon
Description: Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
Study NCT02603341 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton
Description: Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
Study NCT00575081 — intervention group
Intervention type: DEVICE
Intervention: Stereotactic brain procedures
Description: Stereotactic brain procedures
Study NCT03349125 — intervention group
Intervention type: BEHAVIORAL
Intervention: Collar On
Study NCT03349125 — intervention group
Intervention type: BEHAVIORAL
Intervention: Collar Off
Study NCT04098809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 16 French urinary catheter
Description: 16 French urinary catheter
Study NCT04098809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20 French urinary catheter
Description: 20 French urinary catheter
Study NCT03415815 — intervention group
Intervention type: PROCEDURE
Intervention: Surgeries
Description: Radical resection of esophageal cancer
Study NCT00715052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Description: 40 consecutive one hour treatments at 1.5 ATA with 100% O2